Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL594952 | 0.85 | ALDH1A1 (0.50) | NPY5RCA12CA7CA14ALDH1A1 | |
| SCHEMBL2884413 | 0.85 | ALDH1A1 (0.50) | NPY5RCA12CA7CA14ALDH1A1 | |
| SCHEMBL90846 | 0.85 | ALDH1A1 (0.50) | NPY5RCA12CA7CA14ALDH1A1 | |
| SCHEMBL12048931 | 0.84 | CA12 (0.50) | NPY5RCA12CA7CA14ALDH1A1 | |
| SCHEMBL12836912 | 0.84 | NPY5R (0.46) | NPY5RCA12CA7CA14ALDH1A1 | |
| SCHEMBL2901646 | 0.82 | NPY5R (0.45) | NPY5RCA12CA7CA14ALDH1A1 | |
| SCHEMBL2898453 | 0.82 | NPY5R (0.45) | NPY5RCA12CA7CA14ALDH1A1 | |
| SCHEMBL2901644 | 0.82 | NPY5R (0.45) | NPY5RCA12CA7CA14ALDH1A1 | |
| SCHEMBL90832 | 0.81 | NPY5R (0.50) | NPY5RCA12CA7CA14ALDH1A1 | |
| SCHEMBL12436673 | 0.79 | CA12 (0.41) | CA12CA7CA14ALDH1A1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8299066-B2 | Compounds having NPY Y5 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2012-10-30 | — | — | US | disclosed |
| US-20120130070-A1 | COMPOUNDS HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-05-24 | — | — | US | disclosed |
| US-8129372-B2 | Compounds having NPY Y5 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2012-03-06 | — | — | US | disclosed |
| US-20110028468-A1 | COMPOUNDS HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY | Shinonogi & Co., Ltd (JP) | 2011-02-03 | — | — | US | disclosed |
| US-20100035996-A1 | GLUCOSE METABOLISM STIMULATING AGENT | SHIONOGI & CO LTD (JP) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035996-A1 | GLUCOSE METABOLISM STIMULATING AGENT | GPR119, GCKR, GHSR | NPY5R 413/4885CA12 2972/4885CA7 2100/4885 |
| US-20120130070-A1 | COMPOUNDS HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY | NPY5R, NPY1R, NPY2R | NPY5R 1/4885CA12 3484/4885CA7 1691/4885 |
| US-20110028468-A1 | COMPOUNDS HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY | NPY5R, NPY1R, NPY2R | NPY5R 1/4885CA12 3484/4885CA7 1691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.